T2 Biosystems, Inc.
At T2 Biosystems, our mission is to save lives and improve healthcare by empowering clinicians to get patients on the right therapy faster. We come to work every day to solve critical needs in healthcare diagnostics with innovative solutions built on our game-changing T2 Magnetic Resonance (T2MR®) detection technology. Sepsis claims more lives annually than breast cancer, prostate cancer, and AIDS combined. We’re focused on eradicating deaths due to sepsis by developing tools that help identify the most common and deadly sepsis-causing pathogens faster than ever before. Speed is critical in sepsis management. The faster patients receive effective treatment, the more likely they are to survive and have better outcomes. Better yet, early targeted therapy for bloodstream infections may prevent the progression to sepsis altogether.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Medical / Health Care - Occupational Health
- Market Focus:
- Nationally (across the country)
- Year Founded:
- 2006
About Us
Our blood tests provide actionable results in just 3 to 5 hours. The only other way to identify the species-specific diagnosis requires a blood culture, which can take 1 to 5 days or more. Today, T2Direct Diagnostics™ are getting patients on the right therapy faster, and the expedited identification of negative test results allows rapid de-escalation of unneeded therapy. In partnership with hospitals around the world, T2 Biosystems technology is uniquely positioned to strike a huge blow to sepsis and the hundreds of thousands of lives it takes each year.
Our T2Bacteria® and T2Candida® Panels run on the automated T2Dx® Instrument. They are the first and only FDA-cleared and CE-marked blood tests that identify sepsis-causing pathogens without the wait for blood culture. As hospitals continue to adopt our technology, it will represent a paradigm shift that can potentially result in thousands of patients going home to their families instead of the tragic, and potentially avoidable, alternative.
We also have a strong pipeline of products for sepsis management, including bacterial resistance panels and a Lyme disease panel.
Our Mission
At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates, and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies.
T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs.
Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days.
Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum, and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.